Хайлтын үр дүнгүүд - Mathilde Cancel

  • 4-н 1 - 4 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Recurrent<i>PRKAR1A</i>Mutation in Acrodysostosis with Hormone Resistance

    Recurrent<i>PRKAR1A</i>Mutation in Acrodysostosis with Hormone Resistance -н Agnès Linglart, Christine Dos Santos, Alain Couvineau, Colette Auzan, Yasemin Güneş, Mathilde Cancel, Emmanuelle Motte‐Signoret, Graziella Pinto, Philippe Chanson, Pierre Bougnères, Éric Clauser, Caroline Silve

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Efficacy of Savolitinib vs Sunitinib in Patients With<i>MET</i>-Driven Papillary Renal Cell Carcinoma

    Efficacy of Savolitinib vs Sunitinib in Patients With<i>MET</i>-Driven Papillary Renal Cell Carcinoma -н Toni K. Choueiri, Daniel Y.C. Heng, Jae‐Lyun Lee, Mathilde Cancel, Remy B. Verheijen, Anders Mellemgaard, Lone H. Ottesen, Melanie M. Frigault, Anne L’Hernault, Zsolt Szíjgyártó, Sabina Signoretti, Laurence Albigès

    Хэвлэсэн 2020
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study

    Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study -н Mirela Diana Ilie, Chiara Villa, Thomas Cuny, Christine Cortet, Guillaume Assié, Bertrand Baussart, Mathilde Cancel, Philippe Chanson, Bénédicte Decoudier, Élise Deluche, Anna Luisa Di Stefano, D. Drui, S. Gaillard, B. Goichot, Olivier Huillard, Anthony Joncour, Delphine Larrieu‐Ciron, Rossella Libé, Guillaume Nars, Alexandre Vasiljevic, Gérald Raverot

    Хэвлэсэн 2022
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

    Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-lab... -н Yann Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross‐Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwénaëlle Gravis, Nadine Houédé, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, N. Doumerc, P. Paparel, Jean‐Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, G. Pignot, E. Braychenko, Stefano Caruso, Cheng‐Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougoüin, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman‐Rossi, Wolf H. Fridman, Catherine Sautès‐Fridman, Stéphane Oudard

    Хэвлэсэн 2022
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: